MRD testing showed weak trial-level correlation with progression-free survival in BTK inhibitor and venetoclax-based CLL studies.

Adaptive Biotechnologies (ADPT) has attracted fresh attention after reporting first quarter 2026 results, along with higher full year revenue guidance for its Minimal Residual Disease business, ...

TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...

We thank Gang Lv and colleagues for the response to our study.1 We agree that minimal residual disease (MRD) monitoring could help to optimise the treatment of mantle-cell lymphoma with ibrutinib and ...

Q1 2026 Management View "We reported revenue in the first quarter of just over $200 million, coming within our Q1 revenue guidance range" (President, CEO & Director Samraat Raha). "We delivered ...

Biotech Stock Soars 60% in 2024: Cathie Wood's Bold Investment Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue ...

Most oncologists in a recent survey said they lack the knowledge and data to use measurable, or minimal, residual disease (MRD) as a decision-making tool in the treatment of multiple myeloma. A new ...

Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...

Minimal residual disease was “strongly” associated with overall survival at the patient level, researchers reported. Minimal residual disease (MRD) is “a credible intermediate endpoint” for some ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...